Skip to content
← All treatment topics

TREATMENT READING

Thymoma and Thymic Carcinoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

45 sections
  1. General Information About Thymoma and Thymic Carcinoma Treatment
  2. Incidence and Mortality
  3. Autoimmune Paraneoplastic Diseases Associated With Thymoma and Thymic Carcinomas
  4. Clinical Features
  5. Diagnostic and Staging Evaluation
  6. Prognostic Factors and Prognosis
  7. Thymoma
  8. Thymic carcinoma
  9. Follow-Up After Treatment of Thymoma
  10. Treatment Option Overview for Thymoma and Thymic Carcinoma
  11. Capecitabine and Fluorouracil Dosing
  12. Treatment of Thymoma
  13. Stage I and Stage II Thymoma
  14. Treatment options for stages I and II thymoma
  15. Surgery (stage I)
  16. Surgery with or without PORT (stage II)
  17. Stage III and Stage IV Thymoma
  18. Treatment options for operable or potentially operable stages III and IV thymoma
  19. Treatment options for inoperable stages III and IV thymoma
  20. Treatment of Thymic Carcinoma
  21. Treatment Options for Thymic Carcinoma
  22. Treatment of Recurrent Thymoma and Thymic Carcinoma
  23. Treatment Options for Recurrent Thymoma and Thymic Carcinoma
  24. Chemotherapy
  25. Biological therapies
  26. Octreotide with or without prednisone
  27. Sunitinib
  28. Everolimus
  29. Lenvatinib
  30. Surgery
  31. Radiation therapy
  32. Pembrolizumab
  33. Thymoma and thymic carcinoma treatment
  34. Surgery
  35. Radiation therapy
  36. Chemotherapy
  37. Hormone therapy
  38. Targeted therapy
  39. New treatments being tested in clinical trials
  40. Immunotherapy
  41. Patients can enter clinical trials before, during, or after starting their cancer treatment
  42. Thymoma treatment by stage
  43. Treatment of thymic carcinoma
  44. Treatment of recurrent thymoma and thymic carcinoma
  45. Side effects of treatment

Health professional

General Information About Thymoma and Thymic Carcinoma Treatment

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Thymoma and thymic carcinoma, collectively termed thymic epithelial tumors (TETs), are relatively rare tumors arising from the thymus. Although infrequent, TETs are the most common tumors of the anterior mediastinum in adults. TETs, particularly thymomas, have unique biological properties and are associated with autoimmune paraneoplastic diseases. TETs have the lowest tumor mutational burden of all solid tumors in adults. All TETs have malignant potential and the ability to metastasize. The clinical behavior of TETs can vary from relatively indolent to aggressive, resulting in a range of clinical outcomes.

Surgery is the main treatment, especially for early-stage disease. Multimodality therapy, including chemotherapy and radiation therapy, is used to treat locally advanced disease, and systemic therapy alone is indicated for metastatic TETs.[1]

Sources: 1

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · General Information About Thymoma and Thymic Carcinoma Treatment

Incidence and Mortality

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

TETs are relatively rare tumors, representing about 0.2% to 1.5% of all malignancies.[2] The overall incidence of thymoma is 0.13 cases per 100,000 person-years, based on data from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program.[3] Thymic carcinomas account for approximately 20% of all TETs.[4] The 5-year survival rate is 36% for patients with inoperable, locally advanced carcinoma and 24% for patients with metastatic thymoma and thymic carcinoma.[5]

Sources: 2 · 3 · 4 · 5

Health professional · General Information About Thymoma and Thymic Carcinoma Treatment

Autoimmune Paraneoplastic Diseases Associated With Thymoma and Thymic Carcinomas

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Autoimmune paraneoplastic diseases are associated with thymoma but rarely with thymic carcinomas.[6-9]

Sources: 6 · 9

The occurrence of autoimmune paraneoplastic diseases in patients with thymoma is related to defective negative selection of autoreactive T cells. Decreased expression of AIRE, the autoimmune regulator gene, contributes to this process.[10] Thymoma-associated autoimmune paraneoplastic disease also involves an alteration in circulating T-cell subsets.[11,12] The primary T-cell abnormality may be related to the acquisition of the CD45RA+ phenotype on naive CD4+ T cells during terminal intratumorous thymopoiesis, followed by the export of these activated CD4+ T cells into the circulation.[13]

Sources: 10 · 11 · 12 · 13

In addition to T-cell defects, B-cell lymphopenia and the presence of anticytokine antibodies have been observed in patients with thymoma-related immunodeficiency, resulting in an increased risk of developing opportunistic infection.[6,14,15]

Sources: 6 · 14 · 15

The most common autoimmune paraneoplastic diseases associated with thymoma are myasthenia gravis, hypogammaglobulinemia, and autoimmune pure red cell aplasia.

Myasthenia gravis is the most common autoimmune paraneoplastic disease associated with thymoma. In reported series, approximately 30% to 65% of patients with thymoma have been diagnosed with myasthenia gravis.[7,16,17] Patients with thymoma-associated myasthenia gravis can produce autoantibodies to a variety of neuromuscular antigens, particularly the acetylcholine receptor and titin, a striated muscle antigen.[18,19]

Sources: 7 · 16 · 17 · 18 · 19

Thymoma-associated hypogammaglobulinemia (Good syndrome) has a frequency of 5% to 20%, and thymoma-associated autoimmune pure red cell aplasia has a frequency of approximately 4%.[7,14]

Sources: 7 · 14

A variety of other autoimmune paraneoplastic diseases can be associated with TETs and include virtually any organ system.[7,9]

Sources: 7 · 9

Thymoma patients with myasthenia gravis or other autoimmune paraneoplastic diseases are typically diagnosed with early-stage disease and are more likely to undergo complete surgical resection than those who do not have autoimmune paraneoplastic diseases.[9,20] Thymectomy may not significantly improve the course of thymoma-associated autoimmune paraneoplastic disease in all cases.[21,22] The presence of autoimmune paraneoplastic disease also does not appear to be an independent prognostic factor in patients with TETs.[9]

Sources: 9 · 20 · 21 · 22 · 9

Health professional · General Information About Thymoma and Thymic Carcinoma Treatment

Clinical Features

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Most patients with thymoma or thymic carcinoma are asymptomatic at diagnosis.[23] About one-third of patients present with symptoms that arise either from the underlying tumor or from the presence of associated autoimmune paraneoplastic diseases. Typical clinical signs and symptoms include cough, dyspnea, chest pain, hoarseness of voice, phrenic nerve palsy, or signs suggestive of superior vena cava syndrome.[24]

Sources: 23 · 24

Health professional · General Information About Thymoma and Thymic Carcinoma Treatment

Diagnostic and Staging Evaluation

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

TETs are differentiated from a number of nonthymic neoplasms that can present with mediastinal masses, including:[25,26]

Sources: 25 · 26

Germ cell tumors.

Lymphomas.

Stromal tumors.

Metastatic tumors.

Lung cancer.

Nonneoplastic thymic conditions that can present with mediastinal masses include thymic hyperplasia and thymic cysts.

The following tests and procedures may be used to diagnose and stage thymoma and thymic carcinoma:

Physical examination and history.

Chest x-ray. Approximately 50% of thymomas are diagnosed when they are localized within the thymic capsule and do not infiltrate surrounding tissues.[23]

Sources: 23

Computed tomography (CT) scan. CT with intravenous contrast is useful in the diagnosis and clinical staging of thymoma. CT is usually accurate in predicting tumor size, location, and invasion into vessels, the pericardium, and the lungs.[27,28]The appearance of the tumor on CT may indicate the histological tumor type.[25] In a retrospective study involving 53 patients who underwent thymectomy for TETs, CT indicated that smooth contours with a round shape were most suggestive of type A thymomas, and irregular contours were most suggestive of thymic carcinomas. Calcification was suggestive of type B thymomas. In this study, however, CT was found to be of limited value in differentiating type AB, B1, B2, and B3 thymomas.[29]

Sources: 27 · 28 · 25 · 29

Positron emission tomography (PET) scan. Fluorine F 18-fludeoxyglucose (18F-FDG) PET and thallium single-photon emission CT have been reported in small series for diagnosis and evaluation of therapeutic outcomes in thymic carcinoma.[30-33] Two small series reported that 18F-FDG uptake was related to the invasiveness of thymic carcinoma.[32,33] This raises the possibility of 18F-FDG PET use for diagnosis, treatment planning, and monitoring for recurrence. The impact of sensitivity and specificity on clinical therapeutic decisions is yet to be defined.

Sources: 30 · 33 · 32 · 33

Magnetic resonance imaging (MRI). MRI can distinguish TETs from other malignant and benign mediastinal lesions. Chemical-shift MRI can help differentiate TETs from thymic hyperplasia and a normal thymus. Cardiac MRI is the preferred modality to evaluate for the presence of myocardial involvement. An MRI can help identify phrenic nerve involvement and is considered superior to CT for assessing chest wall invasion.[34]

Sources: 34

Thymic carcinoma can metastasize to regional lymph nodes, bone, liver, or lungs. An evaluation for sites of metastases may be warranted.

Health professional · General Information About Thymoma and Thymic Carcinoma Treatment

Prognostic Factors and Prognosis

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

The World Health Organization (WHO) pathological classification of tumors of the thymus and stage correlate with prognosis.[25] The degree of invasion or tumor stage is generally thought to be a more important indicator of overall survival (OS).[27,35,36]

Sources: 25 · 27 · 35 · 36

Health professional · General Information About Thymoma and Thymic Carcinoma Treatment / Prognostic Factors and Prognosis

Thymoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Histological classification of thymoma is not sufficient to distinguish biologically indolent thymomas from thymomas that exhibit aggressive clinical behavior. Although some thymoma histological types are more likely to be clinically aggressive, treatment outcome and the likelihood of recurrence appear to correlate more closely with the invasive/metastasizing properties of the tumor cells.[25,35] Therefore, some thymomas that appear to be relatively benign by histological criteria may behave very aggressively. Independent evaluations of both tumor invasiveness (using staging criteria) and tumor histology may be combined to predict the clinical behavior of a thymoma.

Sources: 25 · 35

Both histological classification of thymomas and stage may have independent prognostic significance.[35,36] A few series have reported the prognostic value of the WHO classifications. Two large retrospective analyses, one with 100 thymoma cases and the other with 178 thymoma cases, showed that disease-free survival at 10 years varied (see Table 1).[37,38] In these series, stage and complete resection were significant independent prognostic factors. Another analysis reported on 273 thymoma patients who were treated over a 44-year period. See Table 1 for the 20-year survival rates.[35]

Sources: 35 · 36 · Table 1 · 37 · 38 · Table 1 · 35

Table 1. Disease-Free Survival (DFS) of Patients With Thymoma by Histological Subtype
StudyHistological Subtype
AABB1B2B3C
a10-year DFS.
b20-year DFS.
[37] (N = 100)a100%100%83%83%36%28%
[38] (N = 178)a95%90%85%71%40%
[35] (N = 273)b100%87%91%59%36%

Sources: Histological Subtype · 37 · 38 · 35

Health professional · General Information About Thymoma and Thymic Carcinoma Treatment / Prognostic Factors and Prognosis

Thymic carcinoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Thymic carcinomas are usually advanced when diagnosed.[39,40] Thymic carcinomas have a greater propensity for capsular invasion, metastases, and recurrence than thymomas. Patients with thymic carcinoma have worse survival than patients with thymoma (5-year survival rate, 30%–50%).[41] In a retrospective study of 40 patients with thymic carcinoma, the OS rates were 38% for 5 years and 28% for 10 years.[39] In another retrospective study evaluating 43 cases of thymic carcinoma, prognosis was found to depend solely on tumor invasion of the brachiocephalic artery.[40]

Sources: 39 · 40 · 41 · 39 · 40

Health professional · General Information About Thymoma and Thymic Carcinoma Treatment

Follow-Up After Treatment of Thymoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Thymoma has been associated with an increased risk of second malignancies. Because of this risk and because thymoma can recur after a long interval, lifelong surveillance should be considered.[22] The measurement of interferon-alpha and interleukin-2 antibodies is helpful in identifying patients with a thymoma recurrence.[42]

Sources: 22 · 42

In a study of 849 cases between 1973 and 1998, there was an excess risk of subsequent non-Hodgkin lymphoma and soft tissue sarcomas following thymoma.[43] Risk of second malignancy does not appear to be related to thymectomy, radiation therapy, or a clinical history of myasthenia gravis.[22,43,44]

Sources: 43 · 22 · 43 · 44

Health professional

Treatment Option Overview for Thymoma and Thymic Carcinoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

The primary treatment for patients with thymoma or thymic carcinoma is surgical resection with en bloc resection for invasive tumors, if possible.[1-3] Depending on tumor stage, multimodality treatment options—including the use of radiation therapy and chemotherapy with or without surgery—may be used.[4,5] The optimal strategy for induction therapy, which minimizes operative morbidity and mortality and optimizes resectability rates and ultimately survival, remains unknown. A review of the management of thymic epithelial tumors has been published.[1]

Sources: 1 · 3 · 4 · 5 · 1

Table 13. Treatment Options for Thymoma and Thymic Carcinoma
StageTreatment Options
Stage I and II thymomaSurgery
Surgery with or without postoperative radiation therapy
Stage III and IV thymoma (operable)Surgery followed by radiation therapy
Induction chemotherapy followed by surgery and radiation therapy
Stage III and IV thymoma (inoperable)Chemotherapy
Chemotherapy followed by radiation therapy
Chemotherapy followed by surgery (if operable) and radiation therapy
Thymic carcinoma (operable)Surgery (en bloc surgical resection) followed by postoperative radiation therapy with or without postoperative chemotherapy.
Thymic carcinoma (inoperable)Chemotherapy
Chemoradiation therapy
Chemotherapy followed by surgery (if operable) and radiation therapy
Recurrent thymoma and thymic carcinomaChemotherapy
Biological therapies
Surgery or radiation therapy in carefully selected cases
Pembrolizumab (under clinical evaluation)

Sources: Stage · Surgery · Surgery with or without postoperative radiation therapy · Surgery followed by radiation therapy · Induction chemotherapy followed by surgery and radiation therapy · Chemotherapy · Chemotherapy followed by radiation therapy · Chemotherapy followed by surgery (if operable) and radiation therapy · Surgery · Chemotherapy · Chemoradiation therapy · Chemotherapy followed by surgery (if operable) and radiation therapy · Chemotherapy · Biological therapies · Surgery · radiation therapy · Pembrolizumab

Health professional · Treatment Option Overview for Thymoma and Thymic Carcinoma

Capecitabine and Fluorouracil Dosing

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[6,7] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[6-8] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[9-11] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[12] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[13]

Sources: 6 · 7 · 6 · 8 · 9 · 11 · 12 · 13

Health professional

Treatment of Thymoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

For patients presenting with a mediastinal mass that is highly suspicious for an early-stage thymic epithelial tumor (TET) and is potentially completely resectable, surgical resection is the preferred initial treatment.[1] Under these circumstances, surgical resection serves as a diagnostic and therapeutic procedure. Complete resection of the tumor can be achieved in nearly all patients with stage I and stage II TETs.

Sources: 1

Postoperative radiation therapy (PORT) is associated with survival benefit and is generally recommended for patients with stage II or stage III disease.[2] Patients with stage IVA disease are usually offered multimodality therapy consisting of induction chemotherapy followed by surgery (if the disease is considered resectable) and PORT.[3-6] Patients with stage IVB disease are treated with definitive chemotherapy.[7-9,9,10] Surgery and radiation therapy usually do not have a role as primary treatment modalities for advanced disease.

Sources: 2 · 3 · 6 · 7 · 9 · 9 · 10

Health professional · Treatment of Thymoma

Stage I and Stage II Thymoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Health professional · Treatment of Thymoma / Stage I and Stage II Thymoma

Treatment options for stages I and II thymoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Treatment options for stage I and stage II thymoma (operable disease) include:

Sources: stage I · stage II

Surgery (stage I).

Sources: Surgery

Surgery with or without PORT (stage II).

Sources: Surgery with or without PORT

Health professional · Treatment of Thymoma / Stage I and Stage II Thymoma / Treatment options for stages I and II thymoma

Surgery (stage I)

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Excellent long-term survival can be obtained after complete surgical excision for patients with a pathological stage I thymoma. There appears to be no benefit to adjuvant radiation therapy after complete resection of encapsulated noninvasive tumors.[1,11]

Sources: 1 · 11

Health professional · Treatment of Thymoma / Stage I and Stage II Thymoma / Treatment options for stages I and II thymoma

Surgery with or without PORT (stage II)

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

For patients with stage II thymomas with pathologically demonstrated capsular invasion, adjuvant radiation therapy after complete surgical excision has been considered a standard of care, despite the lack of prospective clinical trials.[12,13] Most studies use 40 Gy to 70 Gy with a standard fractionation scheme (1.8–2.0 Gy per fraction).

Sources: 12 · 13

The role and risks of adjuvant radiation therapy for patients with completely resected stage II thymomas need further study. To avoid the potential morbidity and costs associated with thoracic radiation, PORT may be reserved for stage II patients when adjacent organs are within a few millimeters or involve the surgical margin (close or positive surgical margins), as determined by both pathological and intraoperative findings.

Evidence (surgery followed by PORT):

Data were obtained from a clinical study of 1,320 Japanese patients.[14] Patients with stage I thymoma were treated with surgery only, and patients with stage II thymoma underwent surgery and additional radiation therapy.

Sources: 14

Data were obtained from a clinical study of 1,320 Japanese patients.[14] Patients with stage I thymoma were treated with surgery only, and patients with stage II thymoma underwent surgery and additional radiation therapy.

Prophylactic mediastinal radiation therapy did not appear to prevent local recurrences effectively in patients with totally resected stage II thymoma.

Some, but not all, retrospective clinical studies show improved local control and survival with the addition of PORT.[2,14-17][Level of evidence C3]

Sources: 2 · 14 · 17 · Level of evidence C3

Other retrospective studies have found no outcome difference in patients treated with or without PORT after complete resection of the thymic tumor.[18-21]

Sources: 18 · 21

Health professional · Treatment of Thymoma

Stage III and Stage IV Thymoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Health professional · Treatment of Thymoma / Stage III and Stage IV Thymoma

Treatment options for operable or potentially operable stages III and IV thymoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Advances in imaging techniques have resulted in more accurate staging of TETs. However, on occasion, stage III thymoma may be difficult to identify before surgery, and invasion of adjacent mediastinal structures may be identified only at the time of surgery.

Surgical resection with curative intent should be considered for all patients deemed to have resectable stage III thymoma after the initial work-up. PORT is offered to all patients, regardless of surgical margin status, because it is associated with longer overall survival (OS).[2]

Sources: 2

Combined-modality treatment consisting of induction chemotherapy followed by surgery and radiation therapy should be considered for all patients with unresectable stage III thymoma. The optimal strategy for induction therapy, which optimizes resectability rates and ultimately survival, is not defined. However, commonly used induction chemotherapy regimens include combinations of cisplatin, doxorubicin, and cyclophosphamide, or cisplatin and etoposide. Rates of response to induction chemotherapy ranged from 79% to 100%, with subsequent resectability rates of 36% to 69%.[3-7,22-25]

Sources: 3 · 7 · 22 · 25

Treatment options for operable or potentially operable stage III and stage IV thymoma include:

Surgery followed by PORT.

Induction chemotherapy followed by surgery and radiation therapy.

Evidence (treatment of stage III and IV operable or potentially operable thymoma):

Data were obtained from a large clinical study of 1,320 Japanese patients.[14] Patients with stage III and stage IV thymoma underwent surgery and multimodality therapy with surgical resection followed by adjuvant therapy consisting of radiation therapy and/or chemotherapy.

Sources: 14

Data were obtained from a large clinical study of 1,320 Japanese patients.[14] Patients with stage III and stage IV thymoma underwent surgery and multimodality therapy with surgical resection followed by adjuvant therapy consisting of radiation therapy and/or chemotherapy.

The Masaoka clinical stage was found to correlate well with prognosis of thymoma and thymic carcinoma.

For patients with stage III or stage IV thymoma, the 5-year survival rates were 93% for patients treated with total resection, 64% for patients treated with subtotal resection, and 36% for patients whose disease was inoperable. These data highlight the prognostic significance of achieving complete surgical resection of the tumor.

Prophylactic mediastinal radiation therapy did not appear to prevent local recurrences effectively in patients with totally resected stage III thymoma.

Adjuvant therapy, including radiation and/or chemotherapy did not appear to improve the prognosis in patients with totally resected stage III or stage IV thymoma.

In a large retrospective study, 1,334 patients diagnosed with malignant thymoma and treated between 1973 and 2005 were identified in a Surveillance, Epidemiology, and End Results (SEER) Program database.[25]

Sources: 25

In a large retrospective study, 1,334 patients diagnosed with malignant thymoma and treated between 1973 and 2005 were identified in a Surveillance, Epidemiology, and End Results (SEER) Program database.[25]

At a relatively short median follow-up of 65 months, radiation therapy did not appear to increase the risk of cardiac mortality or secondary malignancy.

In patients with stage III and stage IV disease (after excluding patients surviving less than 4 months to account for surgical mortality), the routine use of PORT did not appear to improve long-term survival.

In a retrospective study, 476 patients with stage III thymoma who underwent surgical resection were identified using the SEER database. PORT was administered to 322 patients (67.6%).[26]

Sources: 26

In a retrospective study, 476 patients with stage III thymoma who underwent surgical resection were identified using the SEER database. PORT was administered to 322 patients (67.6%).[26]

Patients who received PORT had a median OS of 127 months (95% confidence interval [CI], 100.9–153.1) compared with 105 months (95% CI, 76.9–133.1) in patients treated with surgery alone (P = .038).

Disease-specific survival was significantly improved in patients receiving PORT compared with patients undergoing surgery alone (P = .049).

Different published series have reported long-term survival rates following induction chemotherapy and surgery, with or without radiation therapy and consolidation chemotherapy. The rates have ranged from 50% at 4 years to 77% at 7 years, with 10-year rates of 86% for stage III patients and 76% for stage IV patients.[5,22,23,27]

Sources: 5 · 22 · 23 · 27

Similar survival rates have been reported with preoperative radiation therapy without chemotherapy, particularly if great vessels are involved. Results showed a 5-year OS rate of 77% and a 10-year OS rate of 59%.[28,29]

Sources: 28 · 29

Health professional · Treatment of Thymoma / Stage III and Stage IV Thymoma

Treatment options for inoperable stages III and IV thymoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Treatment options for patients with inoperable stage III and stage IV thymoma include:

Chemotherapy.

Chemotherapy followed by radiation therapy.

Chemotherapy followed by surgery (if operable) and radiation therapy.

The role of surgical debulking for patients with either stage III or stage IVA disease is controversial. Phase II data suggest that prolonged survival can be accomplished with chemotherapy and radiation therapy alone in many patients who present with locally advanced or even metastatic thymoma.[24] The value of surgery may be questioned if complete or, at the very least, near-complete extirpation cannot be accomplished.

Sources: 24

Evidence (treatment of stage III and IV inoperable thymoma):

An intergroup trial conducted in the United States reported a predicted 5-year OS rate of 52% in 26 patients who received the PAC chemotherapy regimen (cisplatin, doxorubicin, cyclophosphamide) followed by radiation therapy without surgery.[24]

Sources: 24

In a series of 30 patients with stage IV or locally progressive recurrent tumor after radiation therapy, the PAC regimen was given.[7][Level of evidence C3]

Sources: 7 · Level of evidence C3

In a series of 30 patients with stage IV or locally progressive recurrent tumor after radiation therapy, the PAC regimen was given.[7][Level of evidence C3]

A 50% response rate was achieved, including three complete responses.

The median duration of response was 12 months.

The 5-year survival rate was 32%.

The ADOC regimen (doxorubicin, cisplatin, vincristine, cyclophosphamide) was given to 37 patients.[8][Level of evidence C3]

Sources: 8 · Level of evidence C3

The ADOC regimen (doxorubicin, cisplatin, vincristine, cyclophosphamide) was given to 37 patients.[8][Level of evidence C3]

A 92% response rate (34 of 37 patients) was achieved, including complete responses in 43% of patients.

A study of combined chemotherapy with cisplatin and etoposide reported:[30][Level of evidence C3]

Sources: 30 · Level of evidence C3

A study of combined chemotherapy with cisplatin and etoposide reported:[30][Level of evidence C3]

A 56% response rate (9 of 16 patients) was achieved.

There was a median response duration of 3.4 years and a median survival of 4.3 years.

Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.[9][Level of evidence C3]

Sources: 9 · Level of evidence C3

Patients with invasive thymoma or thymic carcinoma were treated with four cycles of etoposide, ifosfamide, and cisplatin (VIP) at 3-week intervals.[9][Level of evidence C3]

Nine of 28 evaluable patients had partial responses (32%; 95% CI, 16%–52%).

The median follow-up was 43 months (range, 12.8–52.3).

The median duration of response was 11.9 months (range, <1–26).

The median OS was 31.6 months.

The 1-year survival rate was 89% and the 2-year survival rate was 70%, based on Kaplan-Meier estimates.

These results appear to be inferior to other combinations.

A phase II study evaluated the activity of a combination of carboplatin and paclitaxel in 46 patients with unresectable TETs, including 21 patients with unresectable thymoma.[10][Level of evidence C3]

Sources: 10 · Level of evidence C3

A phase II study evaluated the activity of a combination of carboplatin and paclitaxel in 46 patients with unresectable TETs, including 21 patients with unresectable thymoma.[10][Level of evidence C3]

Nine of 21 patients with thymoma had objective responses (42.9%; 90% CI, 24.5%–62.8%).

The median duration of response in patients with thymoma was 16.9 months (95% CI, 3.1–22.0).

The median progression-free survival for the thymoma cohort was 16.7 months (95% CI, 7.2–19.8); median OS was not reached after median follow-up of 59.4 months.

Health professional

Treatment of Thymic Carcinoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Thymic carcinoma is rare, and the optimal treatment is undefined. For patients with clearly resectable well-defined disease, surgical resection is often the initial therapeutic intervention. For patients with clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy, thoracic radiation therapy, or both have been given.[1] Patients presenting with locally advanced disease are carefully evaluated and undergo multimodality therapy. Patients with poor performance status and high associated operative risks are generally not candidates for these aggressive treatments. Patients with metastatic disease may respond to combination chemotherapy.

Sources: 1

Health professional · Treatment of Thymic Carcinoma

Treatment Options for Thymic Carcinoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Treatment options for patients with operable thymic carcinoma include:[2]

Sources: 2

Surgery (en bloc surgical resection) followed by postoperative radiation therapy (PORT) with or without postoperative chemotherapy.

Treatment options for patients with inoperable thymic carcinoma (stage III and stage IV with vena caval obstruction, pleural involvement, pericardial implants, etc.) include:

Chemotherapy.

Chemoradiation therapy.

Chemotherapy followed by surgery (if operable) and radiation therapy.

In most published studies, surgery has been followed by adjuvant radiation therapy.[3,4] A prescriptive dose range has yet to be identified. Most studies use 40 Gy to 70 Gy with a standard fractionation scheme (1.8–2.0 Gy per fraction).

Sources: 3 · 4

Evidence (surgery followed by PORT with or without postoperative chemotherapy):

In the largest series reported, data were obtained from a clinical study of 1,320 Japanese patients.[5] Patients with thymic carcinoma were treated with PORT or chemotherapy.

Sources: 5

In the largest series reported, data were obtained from a clinical study of 1,320 Japanese patients.[5] Patients with thymic carcinoma were treated with PORT or chemotherapy.

The 5-year survival rates were 67% for patients treated with total resection, 30% for patients treated with subtotal resection, and 24% for patients whose disease was inoperable.

Adjuvant therapy, including radiation or chemotherapy, did not appear to improve the prognosis in patients with thymic carcinoma.

A multi-institutional retrospective outcome analysis of 186 patients with thymic carcinoma has been reported.[5]

Sources: 5

A multi-institutional retrospective outcome analysis of 186 patients with thymic carcinoma has been reported.[5]

The 5-year survival rates for patients with totally resected thymic carcinoma were 81.5% for patients treated with chemotherapy, 46.6% for patients treated with radiation therapy and chemotherapy, 73.6% for patients treated with radiation therapy alone, and 72.2% for patients who received no adjuvant therapy.

This study failed to detect a long-term survival benefit in patients treated with subtotal resection or any statistically significant survival augmentation from the addition of adjuvant radiation to surgical resection.

The authors stipulated that no definitive conclusions could be made regarding the role of adjuvant radiation therapy in thymic carcinoma because of sample size limitations.

The results of these studies call into question conventional thinking regarding the efficacy of an aggressive multimodality approach that includes debulking, radiation therapy, and cisplatin-based chemotherapy.[6-8] While other studies support the addition of adjuvant radiation therapy and chemotherapy, optimum treatment regimens are undetermined.

Sources: 6 · 8

Chemotherapy is the primary treatment modality for patients with inoperable thymic carcinoma. Most regimens used are similar to those used to treat thymoma and include a platinum compound with or without an anthracycline (PAC [cisplatin, doxorubicin, cyclophosphamide], VIP [etoposide, ifosfamide, and cisplatin], ADOC [doxorubicin, cisplatin, vincristine, cyclophosphamide], cisplatin/etoposide, carboplatin/paclitaxel).[1,9-14]

Sources: 1 · 9 · 14

Evidence (chemotherapy):

A phase II study evaluated the combination of carboplatin and paclitaxel in 46 patients with unresectable thymic epithelial tumors, including 23 patients with unresectable thymic carcinoma.[14][Level of evidence C3]

Sources: 14 · Level of evidence C3

A phase II study evaluated the combination of carboplatin and paclitaxel in 46 patients with unresectable thymic epithelial tumors, including 23 patients with unresectable thymic carcinoma.[14][Level of evidence C3]

Five of 23 patients with thymic carcinoma had objective responses (21.7%; 90% confidence interval [CI], 9.0%–40.4%).

The median duration of response in patients with thymic carcinoma was 4.5 months (95% CI, 3.4–9.9).

The median progression-free survival for the thymic carcinoma cohort was 5 months (95% CI, 3.0–8.3) and the median overall survival was 20 months (95% CI, 5.0–43.6) after a median follow-up of 59.4 months.

VIP was used in a prospective North American Intergroup trial.[11]

Sources: 11

VIP was used in a prospective North American Intergroup trial.[11]

Two of 8 patients with thymic carcinoma (25%) had a partial response.

The 1-year survival rate for patients with thymic carcinoma was 75% and the 2-year rate was 50%.

Health professional

Treatment of Recurrent Thymoma and Thymic Carcinoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Health professional · Treatment of Recurrent Thymoma and Thymic Carcinoma

Treatment Options for Recurrent Thymoma and Thymic Carcinoma

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Treatment options for recurrent thymoma and thymic carcinoma include:

Chemotherapy.

Sources: Chemotherapy.

Biological therapies.

Sources: Biological therapies.

Surgery or radiation therapy in carefully selected cases.

Sources: Surgery · radiation therapy

Pembrolizumab (under clinical evaluation).

Sources: Pembrolizumab

Health professional · Treatment of Recurrent Thymoma and Thymic Carcinoma / Treatment Options for Recurrent Thymoma and Thymic Carcinoma

Chemotherapy

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

A number of studies have demonstrated that certain chemotherapy drugs can induce tumor responses as single-agent or combination therapy. These drugs include pemetrexed, gemcitabine, taxanes, capecitabine, or fluorouracil and etoposide. In general, higher response rates have been reported with combinations, however, no randomized trials have been conducted. In most cases of inoperable disease recurrence, single-agent systemic therapy is preferred. Combination chemotherapy can be considered for selected patients who have demonstrated a good response previously, have had a long recurrence-free interval and good performance status, and, in the case of anthracycline-containing regimen, have not received high cumulative doses previously, which can jeopardize safety, especially in relation to cardiac toxicity.[1]

Sources: 1

Evidence (single-agent chemotherapy):

A phase II trial of pemetrexed (500 mg/m2) was conducted in 27 patients with recurrent thymic epithelial tumors (TETs) (16 patients) and recurrent thymic carcinoma (11 patients).[2]

Sources: 2

A phase II trial of pemetrexed (500 mg/m2) was conducted in 27 patients with recurrent thymic epithelial tumors (TETs) (16 patients) and recurrent thymic carcinoma (11 patients).[2]

The objective response rate was 19.2% (95% confidence interval [CI], 6.3%–38.1%) (26.7% [95% CI, 7.8%–55.1%] in patients with thymoma and 9.1% [95% CI, 0.2%–41.3%] in patients with thymic carcinoma).

The median progression-free survival (PFS) was 10.6 months (12.1 months for patients with thymoma vs. 2.9 months for patients with thymic carcinoma).

The median overall survival (OS) was 28.7 months (46.4 months for patients with thymoma vs. 9.8 months for patients with thymic carcinoma).

The median duration of response was 4 months in patients with thymoma (range, 3.26–6.28 months) and 3.8 months in the one patient with thymic carcinoma who had a partial response.

Six of 16 patients achieved objective responses to octreotide (1.5 mg every day subcutaneously) associated with prednisone (0.6 mg/kg every day orally for 3 months, 0.2 mg/kg every day orally during follow-up).[3]

Sources: 3

Evidence (combination chemotherapy):

Thirty patients (22 patients with recurrent thymoma and 8 patients with thymic carcinoma) were enrolled in a phase II trial and treated with capecitabine (650 mg/m2 twice daily on days 1–14) and gemcitabine (1,000 mg/m2 on days 1 and 8 every 3 weeks).[4]

Sources: 4

Thirty patients (22 patients with recurrent thymoma and 8 patients with thymic carcinoma) were enrolled in a phase II trial and treated with capecitabine (650 mg/m2 twice daily on days 1–14) and gemcitabine (1,000 mg/m2 on days 1 and 8 every 3 weeks).[4]

Objective responses were observed in 9 of 22 patients (41%) with thymoma and 3 of 8 patients (38%) with thymic carcinoma.

After a median follow-up of 18 months (range, 15–22), the median PFS was 11 months (range, 6.5–16.5). The median PFS was 11 months for patients with thymoma and 6 months for patients with thymic carcinoma. The overall median PFS was also 11 months.

One-year and 2-year survival rates for the study population were 90% and 66%, respectively.

Health professional · Treatment of Recurrent Thymoma and Thymic Carcinoma / Treatment Options for Recurrent Thymoma and Thymic Carcinoma

Biological therapies

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Octreotide with or without prednisone may induce responses in patients with octreotide scan–positive thymoma. Objective responses have also been observed with sunitinib and everolimus in patients with recurrent TETs.

Health professional · Treatment of Recurrent Thymoma and Thymic Carcinoma / Treatment Options for Recurrent Thymoma and Thymic Carcinoma / Biological therapies

Octreotide with or without prednisone

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Evidence (octreotide with or without prednisone):

In one study, six of 16 patients achieved objective responses to octreotide (1.5 mg every day subcutaneously) associated with prednisone (0.6 mg/kg every day orally for 3 months, 0.2 mg/kg every day orally during follow-up).[3]

Sources: 3

In a study of octreotide with or without prednisone, two complete responses (5.3%) and ten partial responses (25%) were observed among 42 patients.[5]

Sources: 5

Health professional · Treatment of Recurrent Thymoma and Thymic Carcinoma / Treatment Options for Recurrent Thymoma and Thymic Carcinoma / Biological therapies

Sunitinib

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Evidence (sunitinib):

Forty-one patients with recurrent TETs (25 thymic carcinoma, 16 thymoma) were enrolled in a phase II trial and treated with sunitinib at a dose of 50 mg per day administered in 6-week cycles (4 weeks on treatment followed by a 2-week break).[6][Level of evidence C3]

Sources: 6 · Level of evidence C3

Forty-one patients with recurrent TETs (25 thymic carcinoma, 16 thymoma) were enrolled in a phase II trial and treated with sunitinib at a dose of 50 mg per day administered in 6-week cycles (4 weeks on treatment followed by a 2-week break).[6][Level of evidence C3]

After a median follow-up of 17 months, 6 of 23 assessable patients with thymic carcinoma (26%; 90% CI, 12.1%–45.3%; 95% CI, 10.2%–48.4%) had an objective response, and 15 patients (65%; 95% CI, 42.7%–83.6%) achieved disease stabilization. Of 16 patients with thymoma, 1 patient (6%; 95% CI, 0.2%–30.2%) had a partial response, and 12 patients (75%; 47.6%–92.7%) had stable disease.

The median time to response in the thymic carcinoma cohort was 5.6 months (range, 2.7–13.8), and the median duration of response was 16.4 months (range, 1.4–16.4).

The median PFS was 7.2 months (95% CI, 3.4–15.2) for patients with thymic carcinoma and 8.5 months (2.8–11.3) for patients with thymoma.

The median OS was not reached for patients with thymic carcinoma and was 15.5 months (95% CI, 12.6–undefined) in patients with thymoma.

The estimated OS at 1 year was 78% (95% CI, 58.0%–90.4%) for patients with thymic carcinoma and 86% (60.9%–96.1%) for patients with thymoma.

Health professional · Treatment of Recurrent Thymoma and Thymic Carcinoma / Treatment Options for Recurrent Thymoma and Thymic Carcinoma / Biological therapies

Everolimus

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Evidence (everolimus):

A phase II study included 51 patients with recurrent TETs (32 with thymoma and 19 with thymic carcinoma). Patients received oral everolimus at a dose of 10 mg per day.[7][Level of evidence C3]

Sources: 7 · Level of evidence C3

A phase II study included 51 patients with recurrent TETs (32 with thymoma and 19 with thymic carcinoma). Patients received oral everolimus at a dose of 10 mg per day.[7][Level of evidence C3]

Objective responses were observed in 3 of 32 patients (9.4%) with thymoma and in 3 of 19 patients (15.8%) with thymic carcinoma.

The disease-control rate was 88% (thymoma: 93.8%; thymic carcinoma: 77.8%).

After a median follow-up of 25.7 months, the median PFS was 10.1 months (thymoma: 16.6 months; thymic carcinoma: 5.6 months).

The median OS was 25.7 months (thymoma: not reached; thymic carcinoma: 14.7 months).

Health professional · Treatment of Recurrent Thymoma and Thymic Carcinoma / Treatment Options for Recurrent Thymoma and Thymic Carcinoma / Biological therapies

Lenvatinib

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Lenvatinib is an orally administered multikinase inhibitor that targets vascular endothelial growth factor receptors, platelet-derived growth factor receptor-alpha, fibroblast growth factor receptors, c-kit, and the RET proto-oncogene.

Evidence (lenvatinib):

Forty-two patients with recurrent thymic carcinoma were enrolled in a phase II trial and treated with oral lenvatinib at a dose of 24 mg per day in 4-week cycles until disease progression or development of unacceptable adverse events. The primary end point was objective response rate, assessed by independent central review.[8][Level of evidence C3]

Sources: 8 · Level of evidence C3

Forty-two patients with recurrent thymic carcinoma were enrolled in a phase II trial and treated with oral lenvatinib at a dose of 24 mg per day in 4-week cycles until disease progression or development of unacceptable adverse events. The primary end point was objective response rate, assessed by independent central review.[8][Level of evidence C3]

Objective responses were observed in 16 of 42 patients (38%; 90% CI, 25.6%–52.0%).

The disease-control rate was 95% (95% CI, 83.8%–99.4%).

After a median follow-up of 15.5 months, the median time to response was 2.0 months, the median duration of response was 11.6 months (95% CI, 5.8–18.0), the median PFS was 9.3 months (95% CI, 7.7–13.9), and the median OS was not reached (NR) (95% CI, 16.1–NR).

The most common treatment-related adverse events were hypertension (88%), palmar-plantar erythrodysesthesia (69%), thrombocytopenia (52%), and diarrhea (50%).

All patients required at least one dose reduction due to adverse events. Five dose reductions were permitted in this study (20 mg, 14 mg, 10 mg, 8 mg, 4 mg). There were no treatment-related deaths.

Predictive biomarker analysis was not performed as part of this clinical trial.

Health professional · Treatment of Recurrent Thymoma and Thymic Carcinoma / Treatment Options for Recurrent Thymoma and Thymic Carcinoma

Surgery

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Surgical resection may be repeated, particularly for local recurrences and, in some cases, pleural and pericardial implants. Patients with recurrent thymomas who undergo repeat resection of recurrent disease may have prolonged survival when complete resection is attained.[9] However, only a minority of patients may be candidates for resection.

Sources: 9

Evidence (surgery):

In a review of 395 patients who underwent resections for TETs, 67 had tumor recurrence and 22 underwent a repeat resection procedure.[10]

Sources: 10

In a review of 395 patients who underwent resections for TETs, 67 had tumor recurrence and 22 underwent a repeat resection procedure.[10]

The 10-year survival rate was 70%.

In another study, 30 of 266 patients initially treated by total resection of the tumor had a recurrence; in all 30 patients, surgical resection was attempted.[11] Complete resection of the recurrent tumor was obtained in ten cases.

Sources: 11

In another study, 30 of 266 patients initially treated by total resection of the tumor had a recurrence; in all 30 patients, surgical resection was attempted.[11] Complete resection of the recurrent tumor was obtained in ten cases.

The 5-year survival rate was 48%.

The 10-year survival rate was 24%.

Of note, patients in these series may have received chemotherapy and/or radiation therapy in addition to surgery.

Health professional · Treatment of Recurrent Thymoma and Thymic Carcinoma / Treatment Options for Recurrent Thymoma and Thymic Carcinoma

Radiation therapy

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Postoperative radiation therapy has been used for patients with incomplete resections and for selected patients after complete resections of recurrent thymomas.[9] Radiation therapy is also indicated for palliation of symptoms such as pain due to chest wall invasion, and superior vena cava syndrome.

Sources: 9

Health professional · Treatment of Recurrent Thymoma and Thymic Carcinoma / Treatment Options for Recurrent Thymoma and Thymic Carcinoma

Pembrolizumab

Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: October 25, 2024. Captured 2026-09-09.

Pembrolizumab (an anti-programmed death ligand 1 antibody) has been evaluated in patients with recurrent TETs. Immune checkpoint inhibitor therapy is under clinical evaluation and should be used in the context of a clinical trial.

Thirty-three patients with refractory or relapsed TETs (26 with thymic carcinoma, 7 with thymoma) were enrolled in a phase II trial of pembrolizumab.[12]

Sources: 12

Thirty-three patients with refractory or relapsed TETs (26 with thymic carcinoma, 7 with thymoma) were enrolled in a phase II trial of pembrolizumab.[12]

Objective responses were observed in 2 of 7 patients with thymoma (28.6%; 95% CI, 8.2%–64.1%) and in 5 of 26 patients with thymic carcinoma (19.2%; 95% CI, 8.5%–37.9%).

The median PFS was 6.1 months for both groups.

Grade 3 or greater immune-related adverse events were observed in 5 of 7 patients (71.4%) with thymoma and in 4 of 26 patients (15.4%) with thymic carcinoma, including hepatitis (12.1%), myocarditis (9.1%), and myasthenia gravis (6.1%).

Forty-one patients with recurrent thymic carcinoma were enrolled in a single-arm phase II study of pembrolizumab.[13]

Sources: 13

Forty-one patients with recurrent thymic carcinoma were enrolled in a single-arm phase II study of pembrolizumab.[13]

After a median follow-up of 20 months, the objective response rate was 22.5% (95% CI, 10.8%–38.5%).

The median duration of response was 22.4 months (95% CI, 12.3–34.7).

The median PFS was 4.2 months (95% CI, 2.9–10.3), and the median OS was 24.9 months (15.5–NR).

Severe immune-related adverse events were observed in six patients (15%), including two patients (5%) with myocarditis.

For patients

Thymoma and thymic carcinoma treatment

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Thymoma and thymic carcinoma treatment

Different types of treatments are available for patients with thymoma and thymic carcinoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: clinical trials · research study

The following types of treatment are used:

For patients · Thymoma and thymic carcinoma treatment

Surgery

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Surgery to remove the tumor is the most common treatment of thymoma.

Sources: Surgery · tumor

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: radiation therapy · cells · adjuvant therapy

For patients · Thymoma and thymic carcinoma treatment

Radiation therapy

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: x-rays · radiation · External radiation therapy

For patients · Thymoma and thymic carcinoma treatment

Chemotherapy

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: Chemotherapy · drugs · injected · vein · systemic chemotherapy

Chemotherapy may be used to shrink the tumor before surgery or radiation therapy. This is called neoadjuvant chemotherapy.

Sources: neoadjuvant

For patients · Thymoma and thymic carcinoma treatment

Hormone therapy

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Hormone therapy is a cancer treatment that removes hormones or blocks their action and stops cancer cells from growing. Hormones are substances made by glands in the body and flow through the bloodstream. Some hormones can cause certain cancers to grow. If tests show that the cancer cells have places where hormones can attach (receptors), drugs, surgery, or radiation therapy is used to reduce the production of hormones or block them from working. Hormone therapy using octreotide with or without prednisone may be used to treat thymoma or thymic carcinoma.

Sources: Hormone therapy · hormones · glands · receptors · octreotide · prednisone

For patients · Thymoma and thymic carcinoma treatment

Targeted therapy

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors are types of targeted therapies used in the treatment of thymoma and thymic carcinoma.

Sources: Targeted therapy · drugs · Tyrosine kinase inhibitors · mammalian target of rapamycin

TKIs: This treatment blocks signals needed for tumors to grow. Sunitinib and lenvatinib are TKIs that may be used to treat recurrent thymoma or recurrent thymic carcinoma.

Sources: Sunitinib · lenvatinib · recurrent

mTOR inhibitors: This treatment blocks a protein called mTOR, which may keep cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. Everolimus is an mTOR inhibitor that may be used to treat recurrent thymoma or recurrent thymic carcinoma.

Sources: protein · mTOR · blood vessels · Everolimus

For patients · Thymoma and thymic carcinoma treatment

New treatments being tested in clinical trials

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Thymoma and thymic carcinoma treatment / New treatments being tested in clinical trials

Immunotherapy

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer.

Sources: Immunotherapy · immune system

Immune checkpoint inhibitor therapy: PD-1 is a protein on the surface of T cells that helps keep the body’s immune responses in check. PD-L1 is a protein found on some types of cancer cells. When PD-1 attaches to PD-L1, it stops the T cell from killing the cancer cell. PD-1 and PD-L1 inhibitors keep PD-1 and PD-L1 proteins from attaching to each other. This allows the T cells to kill cancer cells. Pembrolizumab is a type of PD-1 inhibitor that is being studied in the treatment of recurrent thymoma and thymic carcinoma.

Sources: Immune checkpoint inhibitor · PD-1 · T cells · immune responses · PD-L1 · Pembrolizumab

For patients · Clinical trials

Patients can enter clinical trials before, during, or after starting their cancer treatment

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Find clinical trials for thymoma and thymic carcinoma at Clinical Trials to Treat Thymoma and Thymic Carcinoma. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: Clinical Trials to Treat Thymoma and Thymic Carcinoma · ClinicalTrials.gov

For patients

Thymoma treatment by stage

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Thymoma treatment by stage

Treatment of stage I and stage II thymoma is surgery, which may be followed by radiation therapy.

Sources: stage I · stage II thymoma · surgery · radiation therapy

Treatment of stage III and stage IV thymoma that may be completely removed by surgery includes the following:

Sources: stage III · stage IV thymoma · surgery

Surgery followed by radiation therapy.

Sources: radiation therapy

Neoadjuvant chemotherapy followed by surgery and radiation therapy.

Sources: Neoadjuvant · chemotherapy

Treatment of stage III and stage IV thymoma that cannot be completely removed by surgery includes the following:

Chemotherapy.

Chemotherapy followed by radiation therapy.

Neoadjuvant chemotherapy followed by surgery (if operable) and radiation therapy.

Sources: operable

For patients

Treatment of thymic carcinoma

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Treatment of thymic carcinoma

Treatment of thymic carcinoma that may be completely removed by surgery includes the following:

Sources: surgery

Surgery followed by radiation therapy with or without chemotherapy.

Sources: radiation therapy · chemotherapy

Treatment of thymic carcinoma that cannot be completely removed by surgery includes the following:

Chemotherapy.

Chemotherapy with radiation therapy.

Chemotherapy followed surgery, if the tumor may be completely removed, and radiation therapy.

For patients

Treatment of recurrent thymoma and thymic carcinoma

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Treatment of recurrent thymoma and thymic carcinoma

Treatment of recurrent thymoma and thymic carcinoma may include the following:

Sources: recurrent

Chemotherapy.

Sources: Chemotherapy

Hormone therapy (octreotide) with or without prednisone.

Sources: Hormone therapy · octreotide · prednisone

Targeted therapy.

Sources: Targeted therapy

Surgery.

Sources: Surgery

Radiation therapy.

Sources: Radiation therapy

A clinical trial of immune checkpoint inhibitor therapy with pembrolizumab.

Sources: clinical trial · immune checkpoint inhibitor · pembrolizumab

For patients

Side effects of treatment

Source: Thymoma and Thymic Carcinoma, National Cancer Institute.

Source updated: January 11, 2023. Captured 2026-09-09.

Side effects of treatment

Treatment for thymoma and thymic carcinoma may cause side effects. For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: Side Effects